Efficacy of oral midazolam for minimal and moderate sedation in pediatric patients: A systematic review

Maria A. Manso1 | Catherine Guittet1 | François Vandenhende2 | Luc-André Granier1

1Clinical Affairs, Advicenne, Nîmes, France
2Statistics, ClinBay, Genappe, Belgium

Correspondence
Maria A. Manso, Clinical Affairs, Advicenne, 2 rue Briçonnet, 30000 Nîmes, France.
Email: mmanso@advicenne.com

Funding information
This study was financed by Advicenne.

Section Editor: Joseph Cravero

Abstract
One of the most widely used options for minimal/moderate sedation in pediatric patients is oral midazolam, as it presents an alternative to less well-accepted routes of administration (e.g., intravenous or intranasal) of this well-known efficacious and well-tolerated short-acting benzodiazepine. A systematic review of the literature was conducted in order to identify clinical studies evaluating the effectiveness of oral midazolam for sedation in pediatric patients in the context of premedication before anesthesia or during diagnostic/treatment procedures. The percentage of respondents (response rate) after single administration of oral midazolam was evaluated and compared versus placebo in a subset of placebo-controlled studies. The range of oral midazolam doses providing effective sedation in the different pediatric age subsets was analyzed in order to assess optimum dosing strategies. A total of 25 pediatric clinical studies, utilizing a variety of measures of sedation effectiveness, were selected. These studies included a total of 1472 patients (aged 4 months-18 years) treated with midazolam (0.25-1.5 mg/kg) and 138 patients treated with placebo. The response rates [95% confidence interval] with oral midazolam ranged from 36.7% [21.6%, 54.9%] to 97.8% [86.1%, 99.7%], while with placebo response rates ranged from 4.0% [0.6%, 23.5%] to 41.0% [29.4%, 53.6%]. When considering the 4 placebo-controlled studies, the odds ratios [95% confidence interval] for the comparison of midazolam vs. placebo ranged from 13.4 [5.0, 36.0] to 25.9 [6.7, 100.6]. The analysis of subgroups by context of sedation showed response rates [95% confidence interval] with oral midazolam ranging from 36.7% [21.6%, 54.9%] to 97.0% [94.8%, 98.3%] for anesthetic premedication and from 56.1% [43.1%, 68.4] to 97.8% [86.1%, 99.7%] for medical procedures. The efficacy of midazolam for pediatric minimal/moderate sedation from a dose of 0.25 mg/kg and above was demonstrated. The probability of occurrence of adverse events and over-sedation increases with increasing doses.

Keywords
benzodiazepines, clinical efficacy, hypnotics and sedatives, pediatrics, preanesthetic medication, randomized trials

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2019 The Authors. Pediatric Anesthesia published by John Wiley & Sons Ltd
1 | INTRODUCTION

It is estimated that more than 50% of children could benefit from minimal to moderate sedation during perioperative or procedural periods to treat or prevent behavioral stress and anxiety, caused by separation from their families, the presence of an unfamiliar environment, or fear of pain.1-4

The objective of minimal/moderate sedation is to enable the accomplishment of a scheduled intervention with a child who is calm, in order to prevent psychological distress prior to or during the intervention, to avoid poor compliance or cancelation, and any potential negative impact on postoperative recovery or other possible long-term psychological consequences.4-6

Midazolam has a very long track record of use for minimal and moderate sedation and remains the most commonly used oral sedative for anxiolysis in children. A recent Cochrane review evaluated midazolam for sedation before procedures and discussed data about the effectiveness of midazolam in adults and pediatric patients (by any route) in comparison with other medications using different outcome measures.7 Among the drugs used for moderate sedation, oral midazolam offers the advantage of being an efficacious, short-acting benzodiazepine, with anxiolytic, sedative, and hypnotic properties, with a favorable benefit/risk ratio.8 Since the late 1980s, a number of clinical trials have been published evaluating the efficacy of oral midazolam for sedation in children; hence, a large volume of information relating to oral midazolam as a sedative in pediatric patients is available. There is, however, a broad range of oral doses used in pediatric patients for minimal/moderate sedation, and the optimum dosing in different contexts of sedation remains unclear.

The major aims of the present review were to summarize and analyze the available literature data related to minimal/moderate sedation with oral midazolam in pediatric patients, both prior to anesthesia and during minor procedures, and to evaluate oral midazolam doses providing effective minimal or moderate sedation in different pediatric age subsets and contexts of sedation.

**FIGURE 1** Flow diagram of study selection process
2 | RESEARCH STRATEGY

2.1 | Literature search

A systematic review of the literature was conducted in order to identify clinical studies evaluating the use of oral midazolam in pediatric patients in the context either of premedication before anesthesia for surgical procedures or during diagnostic or treatment procedures. Articles were identified from electronic resources including PubMed and ScienceDirect (e.g., MEDLINE search (“midazolam”[MeSH Terms] OR “midazolam”[All Fields]) AND “sedation”[All Fields] AND (“child”[MeSH Terms] OR “child”[All Fields] OR “children”[All Fields]) AND (“pediatrics”[MeSH Terms] OR “pediatrics”[All Fields] OR “pediatric”[All Fields]) and by manual searches from further evaluation of key review articles and bibliographies of articles. All studies published or in press between January 1988 and March 2016, and written in English, were considered.

2.2 | Study selection and outcomes

Only randomized studies that assessed the efficacy of midazolam as a sole medication using evaluation scales related to minimal/moderate sedation, and where the effectiveness of oral midazolam for sedation in terms of number of responders with respect to the number of treated children (generally within 30-45 minutes post-administration, and up to 1 hour) was reported, were considered. All studies evaluating moderate sedation using discrete sedation scales were selected.

The outcome used for comparison purposes was the proportion of patients considered adequately sedated for the specific intervention (response rate), as detailed in each study. Studies that used placebo, other drugs, different oral midazolam doses, different oral midazolam preparations, or other routes of administration as comparators were acceptable. Information about comparators used in the different studies was extracted. Observations regarding vital signs and reported adverse events were summarized.

2.3 | Classification of literature data and statistical methods

As shown in Figure 1, the initial search strategy identified 1661 records. A total of 100 articles were assessed for eligibility by full-text assessment by at least 2 reviewers. The 25 articles selected for inclusion in the review involve a total of 1610 patients, aged from 4 months to 18 years old; 1472 patients were treated with a single oral midazolam dose between 0.25 and 1.5 mg/kg, with a maximum dose of 20 mg used most frequently (40 mg in one of the studies), and 138 patients were treated with placebo (Table 1).

A summary description of the individual clinical efficacy studies for both contexts of sedation, including efficacy results per treatment (midazolam and placebo) and dose, is shown in Table 2. The data from the literature were tabulated, indicating the number of subjects, number of responders, and response rates per treatment. Whenever sedation levels only were indicated or different time points were presented, the sedation success criterion was defined as indicated in Table 2.

The response rates (95% CI) and odds ratios (OR, 95% CI) were calculated for the individual studies and depicted graphically. Statistical analyses were carried out using SAS v 9.4 under PC windows.

3 | DISCUSSION

The relevant literature on the use of midazolam in minimal/moderate sedation for children was reviewed. Variability in the assessment of sedation was observed between studies. However, there was a clear superiority of midazolam when compared to placebo in the range of doses evaluated.
| Study          | Blinding | Intervention                  | Evaluation scale (success criterion, evaluation time point) | Type of success criterion | Age range | ASA status | Treatment group (formulation type)                                                                 | Dose (mg/kg) | n/N     | Other comparators | Safety with midazolam                                                                 |
|---------------|----------|-------------------------------|------------------------------------------------------------|---------------------------|-----------|------------|---------------------------------------------------------------------------------------------------|---------------|---------|-------------------|--------------------------------------------------------------------------------------|
| *Anesthetic premedication* |          |                               |                                                            |                           |           |            |                                                                                                   |               |         |                   |                                                                                      |
| Alderson 1994<sup>27</sup> | Double-blind | Ambulatory dental surgery | Sedation 4-point scale (3 = drowsy at induction, 21.8 ± 7.0 min postadministration)<sup>a</sup> | B                         | 1-6 y     | ASA I-II   | Oral midazolam (extemporaneous preparation, mixture of IV form with syrup)                       | 0.5           | 19/20   | Oral ketamine 5 mg/kg | Postoperative pain in 4 children, postoperative vomiting in one child, nightmares after surgery in one child |
| Brosius 2002<sup>10</sup> | Double-blind | Superficial surgical procedure | OAA/S sedation 20-point scale (score ≤ 17, 29.0 ± 4.8 min, range 23-40 min, postadministration) | C                         | 10-18 y   | ASA I-II   | Oral midazolam (extemporaneous preparation, mixture of IV form with syrup)                       | 0.3           | 10/25   | No other comparators | Not reported                                                                          |
| Brosius 2003<sup>13</sup> | Double-blind | Surgical procedure | OAA/S sedation 20-point scale (score ≤ 17, 30 min postadministration) | C                         | 2-10 y    | ASA I-II   | Oral midazolam (extemporaneous preparation, mixture of IV form with syrup)                       | 0.5           | 23/25   | No other comparators | Deep sedation in 10% of the patients                                                   |
| Coté 2002<sup>18</sup> | Double-blind | Surgical procedure | Sedation 5-point scale (3 = relaxed, 4 = drowsy or 5 = asleep, within 30 min postadministration) | A                         | 6 mo-1 y  | ASA I-III  | Oral midazolam (oral syrup, Versed®)                                                             | 0.25          | 45/48   | No other comparators | Before induction: nausea (2 cases at high dose), emesis (one case at each dose). One case of upper airway obstruction with initiation of N<sub>2</sub>O at high dose. Overall incidence of respiratory disorders increased with the dose |
|                |          |                               |                                                            |                           |           |            | Oral midazolam (oral syrup, Versed®)                                                             | 0.5           | 47/49   |                   |                                                                                      |
|                |          |                               |                                                            |                           |           |            |                                                                                                   |               | 50/50   |                   |                                                                                      |
|                |          |                               |                                                            |                           |           |            |                                                                                                   |               |         |                   |                                                                                      |
|                |          |                               |                                                            |                           |           |            |                                                                                                   |               |         |                   |                                                                                      |
| (Continues)    |          |                               |                                                            |                           |           |            |                                                                                                   |               |         |                   |                                                                                      |
| Study            | Blinding      | Intervention                              | Evaluation scale (success criterion, evaluation time point) | Type of success criterion | Age range | ASA status | Treatment group (formulation type)                                      | Dose (mg/kg) | n/N | Other comparators | Safety with midazolam                                                                 |
|------------------|---------------|-------------------------------------------|-------------------------------------------------------------|---------------------------|-----------|------------|---------------------------------------------------------------|--------------|------|-------------------|-------------------------------------------------------------------------------------|
| Damle et al. 2008 | Double-blind  | Premedication for dental surgery under general anesthesia in noncooperative children | Sedation 4-point scale (3 = drowsy, 4 = asleep, 30 min postadministration) | B                         | 2-6 y     | ASA I-II   | Oral midazolam (extemporaneous preparation, mixture with honey) | 0.5          | 9/10 | Oral ketamine 5 mg/kg | Vomiting in 10% of the children                                                     |
| Darlong 2004     | Blind observer | Elective ophthalmic surgery               | Sedation 5-point scale (3 = drowsy or 4 = asleep, 30 min after administration) | B                         | 1-9 y     | ASA I-II   | Oral midazolam (extemporaneous preparation, mixture with honey) | 0.5          | 16/24 | Oral ketamine 6 mg/kg or combination of oral ketamine 3 mg/kg + oral midazolam 0.25 mg/kg | Postoperative nausea and vomiting (25% of the cases)                                |
| Darlong 2011     | Double-blind  | Ophthalmic surgery                        | Sedation 5-point scale (3 = drowsy or 4 = asleep, 30 min after administration) | B                         | 1-10 y    | ASA I-II   | Oral midazolam (extemporaneous preparation, mixture with honey) | 0.5          | 12/29 | Combinations of oral ketamine 3 mg/kg + oral midazolam 0.25 mg/kg or oral ketamine 6 mg/kg + oral midazolam 0.5 mg/kg | Postoperative nausea and vomiting (34.5% of the cases) and one case of irrelevant talking |
| Debnat 2003      | Open          | Minor surgery                             | Sedation 5-point scale (3 = drowsy or 2 = light sleep, 30 min postadministration) | B                         | 1-10 y    | ASA I-II   | Oral midazolam (extemporaneous preparation, mixture of IV form with sugar) | 0.5          | 11/30 | Oral ketamine 6 mg/kg | Preoperatively: euphoria (80%), hiccup (10%). Postoperatively: irritability (70%) |
| Funk 2000        | Double-blind  | Surgery of duration > 30 min              | Sedation 4-point scale (3 = drowsy or 4 = asleep, 20 min postadministration at transfer to the operating room) | B                         | 2-10 y    | ASA I-II   | Oral midazolam (extemporaneous preparation, mixture with syrup) | 0.5          | 22/38 | Oral ketamine 6 mg/kg or combination of oral ketamine 3 mg/kg + oral midazolam 0.5 mg/kg | Before induction: 1 vertigo, 3 psychedelic symptoms, 1 excitement, 6 salivation |
| Ghai 2005        | Double-blind  | Surgery                                   | Sedation 4-point scale (1 = asleep, 2 = drowsy or 3 = calm, 20 ± 5.6 min from administration to induction of anesthesia) | A                         | 10 mo-6 y | ASA I-II   | Oral midazolam (IV form, administered orally)                | 0.5          | 46/48 | Combination of oral ketamine 2.5 mg/kg + oral midazolam 0.25 mg/kg | Nausea and vomiting in 3 patients                                                  |

(Continues)
**TABLE 2 (Continued)**

| Study          | Blinding | Intervention                  | Evaluation scale (success criterion, evaluation time point) | Type of success criterion | Age range | ASA status | Treatment group (formulation type) | Dose (mg/kg) | n/N | Other comparators | Safety with midazolam |
|----------------|----------|--------------------------------|-------------------------------------------------------------|---------------------------|-----------|------------|------------------------------------|--------------|-----|-------------------|-----------------------|
| Kogan 2002³¹   | Double-blind | Minor surgery under general anesthesia | Sedation 3-point scale (2 = drowsy or 3 = asleep, around 30 min postadministration) | B                         | 1-5 y     | ASA I-II   | Oral midazolam (extemporaneous preparation, mixture with syrup) | 0.5          | 23/29 | Intranasal midazolam 0.3 mg/kg or rectal midazolam 0.5 mg/kg or sublingual midazolam 0.3 mg/kg | No complications observed |
| Levine 1993a³⁴ | Blind observer | Ambulatory surgery | Sedation 4-point scale (2 = awake/calm or 3 = drowsy, 10-30 min postadministration, at separation from parents) | A                         | 1-6 y     | ASA I-II   | Oral midazolam (extemporaneous preparation, mixture of IV form with syrup) | 0.5          | 27/30 | Comparison of different times of separation from parents | Mean HR and systolic BP values increased at mask application compared with baseline |
| Levine 1993b³⁵ | Open | Cardiac surgery (congenital cardiac disease) | Sedation 4-point scale (2 = awake/calm or 3 = drowsy, 30 min postadministration, at separation from parents) | A                         | 1-6 y     | ASA ≥ II   | Oral midazolam (extemporaneous preparation, mixture with syrup) | 0.75         | 11/15 | Oral or rectal pentobarbital 2 mg/kg + intramuscular morphine 0.2 mg/kg and atropine 0.02 mg/kg | No clinically significant changes in HR and SpO₂ |
| Liacouras 1998³⁵ | Double-blind | IV line placement before endoscopy | Sedation 4-point scale (alert/aware, drowsy/not sleeping and sleeping, pre-IV line placement around 20 min postadministration) | A                         | 2-18 y    | ASA I-II   | Oral midazolam (extemporaneous preparation, mixture of IV form with syrup) | 0.5          | 56/62 | No other comparators | Similar frequency of minor side effects with midazolam (26%) and with placebo (25%) |
| Marshall 2000⁹ | Double-blind | Surgery under general anesthesia or minor procedure | Sedation 5-point scale (3 = drowsy, or 4/5 = asleep, within 30 min postadministration) | B                         | 6 mo-15 y | ASA I-III  | Oral midazolam (oral syrup, Versed®) | 0.25         | 18/28 | No other comparators | 11 adverse events in 21% of the patients |
|                |          |                                |                                                             |                           |           |            |                                   | 0.5          | 20/24 |                   | 19 adverse events in 46% of the patients |
|                |          |                                |                                                             |                           |           |            |                                   | 0.5          | 1     |                   | 22 adverse events in 42% of the patients |

(Continues)
| Study                | Blinding          | Intervention                                           | Evaluation scale (success criterion, evaluation time point) | Type of success criterion | Age range | ASA status | Treatment group (formulation type) | Dose (mg/kg) | n/N | Other comparators | Safety with midazolam |
|----------------------|-------------------|--------------------------------------------------------|-------------------------------------------------------------|---------------------------|-----------|------------|-----------------------------------|--------------|-----|--------------------|----------------------|
| Masue 2003<sup>23</sup> | Open              | Cardiovascular surgery (congenital heart disease)     | Sedation 5-point scale (3 = calm, 4 = drowsy or = asleep, 30 min post administration) | A                         | 4 mo-2 y  | ASA ≥ II   | Oral midazolam (extemporaneous preparation, mixture of IV form with syrup) | 0.5          | 7/20 | No other comparators | Severe salivation and drop in SpO2 in 4 children. Upper airway compromise in 4% of the cases at high dose |
| McMillan 1992<sup>36</sup> | Double-blind      | Minor surgery                                          | Sedation 4-point scale (2 = calm or 3 = drowsy at time of separation from parents, 30 min post administration) | A                         | 1-6 y     | ASA I-II   | Oral midazolam (extemporaneous preparation, mixture of IV form with syrup) | 0.5          | 15/20| No other comparators | No AEs |
| Sheta and AlSarheed 2009<sup>21</sup> | Double-blind      | Premedication for dental surgery under general anesthesia in noncooperative children | Sedation 5-point scale (2 = calm or 3 = drowsy, in the operating room before induction, premedication was 30 min before parental separation) | A                         | 2-6 y     | ASA I-II   | Oral midazolam (extemporaneous preparation, mixture of IV form with juice) | 0.5          | 13/20| No other comparators | 1 and 4 cases of over-sedation at 0.75 and 1.0 mg/kg, respectively. Delayed recovery at 1.0 mg/kg |
| Talon 2009<sup>30</sup> | Blind observer    | Reconstructive surgery under general anesthesia        | Sedation 4-point Ramsey-like scale (1 = sleepy or 2 = alert/calm on arrival in the operating room, administration 30-45 min before surgery) | A                         | 1-18 y    | UNK        | Oral midazolam (oral syrup, Roxane Laboratory.) | 0.5          | 41/50| No AEs observed     | No AEs observed       |
| Study                  | Blinding | Intervention                          | Evaluation scale (success criterion, evaluation time point)                                                                 | Type of success criterion | Age range | ASA status | Treatment group (formulation type) | Dose (mg/kg) | n/N | Other comparators | Safety with midazolam |
|-----------------------|----------|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------|---------------------------|-----------|------------|----------------------------------|--------------|-----|-------------------|-----------------------|
| Jain 2010             | Double-blind | Venepuncture before CT imaging       | Sedation 5-point scale based on behavior (3 = calm or 4 = drowsy, 20-30 min postadministration) *                       | A                         | 1-5 y     | ASA I-II  | Oral midazolam (extemporaneous preparation, mixture with honey) | 0.5          | 24/29 | Combination of oral ketamine 1.0 mg/kg + oral midazolam 0.25 mg/kg | Not reported |
| Klein 2011            | Blind observer | Laceration repair                    | Sedation 5-point scale (3 = drowsy or 4 = calm, during procedure 11-68 min postdose, median 34 min)                   | A                         | 6 mo-7 y  | ASA I-II  | Oral midazolam (oral syrup, Roxane Laboratory) | 0.5 (max. 15 mg) | 32/57 | Intranasal midazolam 0.3 mg/kg or buccal midazolam 0.3 mg/kg | 1 deep sedation; 1 pre- and 1 postdischarge vomiting, 1 postdischarge nightmares |
| Shapira et al 2004    | Double-blind | Dental treatment under N2O 50% in noncooperative children | Sedation 5-point scale (2 = quiet>50% of the time, 1 = quiet>50% of the time, just before the procedure, 20-30 min after administration) | A                         | 1-4 y     | ASA I-II  | Oral midazolam (extemporaneous preparation, liquid) | 0.5          | 23/28 | Combination of hydroxyzine 3.7 mg/kg + oral midazolam 0.3 mg/kg | Vital signs remained stable |
| Silver et al 1994     | Double-blind | Dental procedure in noncooperative children | Successful sedation (glazed look or delayed eye movements, lack of muscle coordination, slurred speech or sleep, onset of sedation 25-30 min after administration. | B                         | 3-18 y    | ASA UNK   | Oral midazolam (extemporaneous preparation, IV form with grape-flavored suspension) | 0.3          | 12/16 | No other comparators | No clinical signs of compromised respiratory rate. No postoperative complications |
| Wilson 2002           | Open      | Dental procedure                       | Sedation Brietkopf and Buttner 4-point scale for emotional status (3 = inactive or 4 = sleepy in 5-65 min, median = 20 min) * | B                         | 10-16 y   | ASA I-II  | Oral midazolam (extemporaneous preparation, mixture with syrup) | 0.5          | 45/46 | Nitrous oxide 30% in oxygen via a nasal mask | No major AEs reported. 1 paradoxical reaction (disinhibition) |
| Wilson 2006           | Open      | Dental extraction under local anesthesia | Sedation Brietkopf and Buttner 4-point scale for emotional status (3 = inactive or 4 = sleepy in 2-30 min, mean = 15.9 min) * | B                         | 5-10 y    | ASA I-II  | Oral midazolam (extemporaneous preparation, mixture with syrup) | 0.3          | 32/35 | Nitrous oxide 30% in oxygen via a nasal mask | Drowsiness and headache on returning home in 20% of the children |

Abbreviations: A, nonrestrictive success criterion; AEs, adverse events; ASA, American Society of Anesthesiologists; B, restrictive success criterion; C, success criterion based on the OAA/S score; CT, computerized tomography; IV, intravenous; Max., maximum; Min., minimum; n, number of responders; N, number of subjects; OAA/S, Observer’s Assessment of Alertness/Sedation; UNK, unknown.

*Success criteria defined a posteriori.
3.1 | Evaluation of effectiveness

Sedation was measured using a variety of discrete sedation scales, with a sedation success criterion defined for each study. The scales used in the studies for the evaluation of sedation in the present review were mainly 3- to 5-point scales, and two studies were identified that utilized the Observer’s Assessment of Alertness/Sedation (OAA/S) scale. It was, however, not possible to find a group of studies with perfectly consistent and relevant success criteria. Also, it was noted that the sedation levels “drowsy” or “awake but calm” could have slightly different meanings depending on the studies and that there could be a level of overlap of terminology between studies. The difficulty in finding a homogeneous group of studies in terms of sedation outcomes, together with the low quality of evidence of most of the studies (study limitations, imprecision, and risk of bias), precluded a meta-analysis with a direct comparison of the effectiveness of midazolam at various doses, despite the amount of available data.

Nevertheless, the objective of this review was to report the data collected on the experience with oral midazolam in producing effective minimal/moderate sedation, and, as such, the different assessment methods were described as part of the reporting of results. However, conclusions could only be drawn from the results of individual studies. The difficulty in comparing the results from the different studies highlights the need to use validated scales for the evaluation of sedation.

The review of the selected articles indicated that three types of studies could be distinguished, according to the type of success criterion: (a) those using nonrestrictive criteria (ie, including awake/calm children as responders); (b) those using more restrictive criteria (ie, requiring at least drowsiness for a successful response); and (c) those using a criterion based on a sedation threshold using a validated scale, the Observer’s Assessment of Alertness/Sedation (OAA/S) scale (ie, effective sedation defined as a score of 17 or less in the 20-point scale).10 As expected, it was observed that the response rates tended to decrease when the type of success criterion became more restrictive (see Table 2).

The most restrictive criterion used the OAA/S scale, specifically designed to evaluate drug-induced sedation with benzodiazepines. The OAA/S scale was methodologically validated and evaluated for its reliability with midazolam in healthy adult subjects and has shown a high discriminatory power and a high sensitivity, using its composite score or sum score.11 Correlation was shown between OAA/S and other commonly used scales.12

The 3- to 5-point scales are commonly used in current medical practice where frequent monitoring is required. Compared to the OAA/S scale, these scales can be rated more quickly (single global clinical assessment), and the rating can be more easily repeated in a short period of time (eg, every 10 minutes during a 45 minutes period) to evaluate the evolution of sedation from midazolam administration up to the start of the procedure or anesthesia induction. Rating is more subjective with 3- to 5-point scales, and the OAA/S scale is more reliable for measuring sedation in clinical studies; however, only two studies were found using the OAA/S scale for the evaluation of sedation oral midazolam and fulfilling the selection criteria.10,13

The variability of the rating scales used clearly contributes to the heterogeneity in the response rates observed in the different studies. The observed heterogeneity could be further explained by the context of sedation, and the age of the patients and the dose, but other elements of the design or the methodologies used in the different studies (eg, time of evaluation of sedation) and population characteristics (eg, their ASA status and the presence of heart disease), could also contribute to this heterogeneity.

3.2 | Effectiveness in different contexts of sedation

A total of 19 trials (N = 1352) reported response rates in the context of anesthetic premedication (including 3 placebo-controlled studies) and only 6 trials (N = 258) reported response rates in the context of medical procedures (including 1 placebo-controlled study). The studies presented high variability, with response rates [95% confidence interval] in anesthetic premedication ranging from 36.7% [21.6%, 54.9%] to 97.0% [94.8%, 98.3%] and from 56.1% [43.1%-68.4] to 97.8% [86.1%, 99.7%] in medical procedures (Figure 2).

Although it could be argued that different sedation criteria should be used between premedication and sedation before procedures, the reality of the studies was that differences observed in sedation scales or success criteria were not associated with the context of sedation (there were studies with nonrestrictive and more restrictive success criteria both for medical procedures and for premedication before anesthesia). There was no apparent difference in terms of response rates between both contexts of sedation.

Only six of the studies fulfilled the selection criteria for sedation before procedures, and therefore, limited information could be gathered from studies performed in this indication. The effectiveness of midazolam in children undergoing procedures, such as dental treatment, has already been reported in a previous review.14

3.3 | Midazolam vs placebo

Only 4 trials compared midazolam (N = 176) to placebo (N = 138). The number of responders with midazolam and with placebo in the individual studies is shown in Figure 3. The response rates estimated ranged from 36.7% [21.6%, 58.9%] to 97.8% [86.1%, 99.7%] with oral midazolam and from 4.0% [0.6%, 23.5%] to 41.0% [29.4%, 53.6%] with placebo.

The “placebo-effect” observed may be explained by the fact that calm children were considered as responders in most of the placebo-controlled studies, regardless of their level of nervousness at baseline. Indeed, epidemiological data suggest that while 60% of children are anxious prior to undergoing surgery or a medical procedure, the rest may remain calm before an intervention.4
## Anesthetic premedication

| Study                      | Doses (mg/kg) | n / N | Response rate (%) (95% CI) |
|----------------------------|---------------|-------|---------------------------|
| Alderson and Lerman 1994   | 0.5           | 19 / 20 | 95.0 (71.8, 99.3)         |
| Brosius and Bannister 2002 | 0.3           | 10 / 25 | 40.0 (23.0, 59.7)         |
| Brosius and Bannister 2003 | 0.5           | 39 / 50 | 78.0 (64.5, 87.4)         |
| Coté et al 2002            | 0.25–1.0      | 385 / 397 | 97.0 (94.8, 98.3)        |
| Damle et al 2008           | 0.5           | 9 / 10  | 90.0 (53.3, 98.6)         |
| Darlong et al 2004         | 0.5           | 16 / 24 | 66.7 (46.1, 82.4)         |
| Darlong et al 2011         | 0.5           | 12 / 29 | 41.4 (25.2, 59.6)         |
| Debnath and Pande 2003     | 0.5           | 11 / 30 | 36.7 (21.6, 54.9)         |
| Funk et al 2000            | 0.5           | 22 / 38 | 57.9 (41.9, 72.4)         |
| Ghai et al 2005            | 0.5           | 46 / 48 | 95.8 (84.8, 99.0)         |
| Kogan et al 2002           | 0.5           | 23 / 29 | 79.3 (61.0, 90.4)         |
| Levine et al 1993          | 0.5           | 27 / 30 | 90.0 (73.2, 96.7)         |
| Levine et al 1993b         | 0.75          | 11 / 15 | 73.3 (46.7, 89.6)         |
| Liacuras et al 1998        | 0.5           | 56 / 62 | 90.3 (80.1, 95.6)         |
| Marshall et al 2000        | 0.25–1.0      | 69 / 85 | 81.2 (71.5, 88.1)         |
| Masue et al 2003           | 0.5–1.5       | 148 / 184 | 80.4 (74.1, 85.5)       |
| McMillan 1992              | 0.5–1.0       | 44 / 60 | 73.3 (60.8, 83.0)         |
| Sheta and Al-Sarheed 2009  | 0.5–1.0       | 45 / 60 | 75.0 (62.6, 84.3)         |
| Talon et al 2009           | 0.5           | 41 / 50 | 82.0 (68.9, 90.4)         |

## Medical procedures

| Study                      | Doses (mg/kg) | n / N | Response rate (%) (95% CI) | OR (95% CI) |
|----------------------------|---------------|-------|---------------------------|-------------|
| Jain et al 2010            | 0.5           | 24 / 29 | 82.8 (64.7, 92.6)         |             |
| Klein et al 2011           | 0.5           | 32 / 57 | 56.1 (43.1, 68.4)         |             |
| Shapiro et al 2004         | 0.5           | 23 / 28 | 82.1 (63.6, 92.4)         |             |
| Silver et al 1994          | 0.3–0.5       | 21 / 31 | 67.7 (49.7, 81.7)         |             |
| Wilson et al 2002          | 0.5           | 45 / 46 | 97.8 (86.1, 99.7)         |             |
| Wilson et al 2006          | 0.3           | 32 / 35 | 91.4 (76.6, 97.2)         |             |

**Figure 2** Response rates (95% CI) in the different contexts of sedation in pediatric patients receiving oral midazolam. n: number of responders, N, number of subjects.

**Figure 3** Number of responders with midazolam and placebo and OR (95% CI) calculated for the studies comparing midazolam vs placebo in the different contexts of sedation. n, number of responders, N, number of subjects.
The OR [95% CI] ranged from 13.4 [5.0, 36.0] to 16.5 [1.9, 138.0] for studies in premedication before anesthesia. The OR obtained for the single placebo-controlled study in procedural sedation was 25.9 [6.7, 100.6] (Figure 3). Despite the observed heterogeneity, all the individual ORs estimated were clearly in favor of a statistically significantly superior response rate with midazolam when compared to placebo.

### 3.4 | Comparison of midazolam doses

The dose most frequently used in the trials, irrespective of the context of sedation, was 0.5 mg/kg. Among all trials, 5 reported response rates at 0.25-0.3 mg/kg (N = 236), 22 at 0.5 mg/kg (N = 811), 3 at 0.75 mg/kg (N = 55), 5 at 1.0 mg/kg (N = 234), and 1 at 1.5 mg/kg (N = 136). Six of the trials presented dose comparisons. In most cases, statistically significantly higher response rates were shown at doses of 1.0 or 1.5 mg/kg as compared to doses of 0.25 or 0.5 mg/kg. However, no statistically significant differences were shown between 0.25 and 0.5 mg/kg doses or between 0.75 and 1.0 mg/kg doses.

Some reports conclude that small doses of midazolam (0.25-0.5 mg/kg) are highly effective and that little advantage is gained by increasing the dose (0.75-1.5 mg/kg). Among them is a very well-designed study that enrolled 397 patients and used a 5-point scale to demonstrate satisfactory sedation at 3 midazolam doses (0.25, 0.5 and 1.0 mg/kg), where response rates of 93.2% (123/132), 97.7% (129/132), and 100% (133/133), respectively, were observed. Two out of the six studies that evaluated different doses did not observe a dose-response trend and obtained higher response rates at low doses than at high doses.

In noncooperative children, midazolam was shown to be efficacious for dental procedures, both when used as premedication before general anesthesia (0.5-1.0 mg/kg) and for sedation (0.3-0.5 mg/kg). Some reports indicate that small doses of midazolam (0.25-0.5 mg/kg) are highly effective and that little advantage is gained by increasing the dose (0.75-1.5 mg/kg). Among them is a very well-designed study that enrolled 397 patients and used a 5-point scale to demonstrate satisfactory sedation at 3 midazolam doses (0.25, 0.5 and 1.0 mg/kg), where response rates of 93.2% (123/132), 97.7% (129/132), and 100% (133/133), respectively, were observed. Two out of the six studies that evaluated different doses did not observe a dose-response trend and obtained higher response rates at low doses than at high doses.

### 3.5 | Effectiveness considering different age groups

The age of the patients included in the different studies is shown in Table 2. The age groups considered in the studies were generally not in agreement with standard ICH pediatric classification, precluding comparison between studies.

When assessed individually, the single study (N = 397) evaluating the efficacy of midazolam in different age groups indicated that, although more children in the youngest group were agitated at baseline, the response rates with midazolam according to sedation criteria were not significantly different across ages, with overall response rates of 97, 96, and 98% for children 6 months to <2 years, 2 to <6 years, and 6 to <16 years, respectively.

### 3.6 | Safety

Descriptive and/or quantitative safety information from the selected studies has been summarized in Table 2. The main adverse events observed were paradoxical reactions, nausea and vomiting and respiratory events. According to the available safety data from the studies, higher midazolam doses generally resulted in a higher incidence of adverse events and of cases of over-sedation (particularly 1-1.5 mg/kg doses). It has been shown that doses of midazolam higher than 0.5 mg/kg may be associated with increased levels of adverse events such as loss of balance and head control, dysphoria and blurred vision, hypotension, respiratory depression, dysphoric reactions, and ataxia and lead to a higher incidence of deep sedation. Cases of deep sedation with an oral dose of 0.5 mg/kg have also been reported.

It was noted that some of the adverse events reported are observed when oral midazolam is used in combination with other drugs (following induction of anesthesia, or after administration of treatments used for local anesthesia, or other medications required for the respective interventions) and can therefore not be attributed to midazolam treatment exclusively.

### 3.7 | Oral midazolam products used

Some of the studies were performed using commercial oral syrups of midazolam (five studies, N = 614), but the majority used liquid extemporaneous preparations made from existing parenteral formulations, generally mixed with syrups or flavorings to improve palatability (21 studies, N = 810). Unfortunately, these extemporaneous preparations suffer from a lack of standardization, particularly with regard to pH, concentration, and ingredients. In one of the studies, the parental form was administered by the oral route without preparation (N = 48). Considering the high solubility and absorption of midazolam, provided there is adequate solubilization of midazolam in the preparation, these different liquid forms cannot be considered to be different in terms of bioavailability, as the limiting factor for midazolam is first-pass metabolism.

### 3.8 | Other comparators

Certain studies used other drugs (ketamine, dexmedetomidine, pentobarbitone, hydroxyzine, nitrous oxide, alone or in combination with midazolam or with other medications) as comparators (12 studies, N = 392 treated with midazolam, N = 417 treated with other drugs), and others compared oral midazolam with alternative routes of administration (2 studies, N = 86 treated with midazolam, N = 194 treated by other routes of administration), as summarized in Table 2. Among the studies reviewed, some compared oral midazolam 0.5 mg/kg to oral ketamine 5-6 mg/kg and demonstrated that both presented similar efficacy. However, ketamine is characterized by undesirable effects, such as excessive salivation, emesis, vertigo, and hallucinations, and midazolam has been reported to afford shorter recovery times than ketamine.

One of the studies indicated that midazolam 0.5 mg/kg and intranasal administration of dexmedetomidine 2 µg/kg were...
comparable in terms of response rates, although intranasal dexmedetomidine could be more useful when the intervention requires sleep induction.\textsuperscript{20}

When compared to other alternative noninvasive routes, midazolam (0.5 mg/kg) administered orally produced equivalent response rates as rectal (0.5 mg/kg), intranasal (0.3 mg/kg), and sublingual (0.3 mg/kg) midazolam. Intranasal presented the most rapid onset of action but was less well-tolerated.\textsuperscript{31,32}

Most of these alternative medications are used off-label in children.

4 | CONCLUSION

Oral midazolam is an efficacious medication with an adequate safety profile for use in minimal or moderate sedation in children from 4 months to 18 years old at doses from 0.25 to 1.5 mg/kg. The incidence of adverse events, such as paradoxical reactions and respiratory events, and the risk of over-sedation increase with increasing doses. Oral midazolam compares well with other alternative noninvasive medications. The need to use validated scales for the evaluation of sedation in future studies is highlighted.

CONFLICT OF INTEREST

MA Manso, C. Guittet and LA Granier are employees of Advicenne and hold stock options or shares in the company.

ORCID

Maria A. Manso https://orcid.org/0000-0002-5056-9065

REFERENCES

1. KainZN,MayesLC,O’ConnorTZ,CicchettiDV. Preoperative Anxiety in Children. Arch Pediatr Adolesc Med. 1996;150(12):1238–1245.
2. Rosenbaum A, Kain ZN, Larsson P, Lonnqvist PA, Wolf AR. The place of premedication in pediatric practice. Pediatr Anesth. 2009;19(9):817-828.
3. Brewer S, Gleditsch SL, Syblik D, Tietjens ME, Vacik HW. Pediatric Anxiety: Child Life Intervention in Day Surgery. J Pediatr Nurs. 2006;21(1):13-22.
4. Kain ZN, Mayes LC, Caldwell-Andrews AA, Karas DE, McClain BC. Preoperative anxiety, postoperative pain, and behavioral recovery in young children undergoing surgery. Pediatrics. 2006;118(2):651-658.
5. Cote CJ, Wilson S. Guidelines for monitoring and management of pediatric patients before, during, and after sedation for diagnostic and therapeutic procedures: Update 2016. Pediatrics. 2016;138(1):1-31.
6. Kain ZN, Caldwell-Andrews AA, Maranets I, et al. Preoperative anxiety and emergence delirium and postoperative maladaptive behaviors. Anesth Analg. 2004;99(6):1648-1654.
7. Conway A, Rolly J, Sutherland JR. Midazolam for sedation before procedures. Cochrane Database Syst Rev. 2016;2016(5):CD009491.
8. Model W. List of Essential Medicines for Children. 5th List. April 2015 (amended August 2015).
9. Marshall J, Rodarte A, Blumer J, Khoo KC, Akbari B, Kearns G. Pediatric pharmacodynamics of midazolam oral syrup. Pediatric Pharmacology Research Unit Network. J Clin Pharmacol. 2000;40(6):578-589.
10. Brosius KK, Bannister CF. Oral midazolam premedication in preadolescents and adolescents. Anesth Analg. 2002;94(1):31-36.
11. Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the Observer's Assessment of Alertness/Sedation scale: study with intravenous midazolam. J. Clin. Psychopharmacol. 1990;10(4):244-251.
12. Malviya S, Voepel-Lewis T, Tait AR, Merkel S, Tremper K, Naughton N. Depth of sedation in children undergoing computed tomography: validity and reliability of the University of Michigan Sedation Scale (UMSS). Br J Anaesth. 2002;88(2):241-245.
13. Brosius KK, Bannister CF. Midazolam premedication in children: a comparison of two oral dosage formulations on sedation score and plasma midazolam levels. Anesth Analg. 2003;96(2):392-395.
14. Lourenco-Matharu L, Ashley PF, Furness S. Sedation of children undergoing dental treatment. Cochrane Database Syst Rev. 2012;14(3)1-106.
15. Liacouras CA, Mascarenhas M, Poon C, Wenner WJ. Placebo-controlled trial assessing the use of oral midazolam as a premedication to conscious sedation for pediatric endoscopy. Gastrointest Endosc. 1998;47(6):455-460.
16. McMillan CO, Spahr-Schopfer IA, Sikich N, Hartley E, Lerman J. Premedication of children with oral midazolam. Can J Anaesth. 1992;39(6):545-550.
17. Jain K, Ghati B, Saxena AK, Saini D, Khandelwal N. Efficacy of two oral premedicants: midazolam or a low-dose combination of midazolam-ketamine for reducing stress during intravenous cannulation in children undergoing CT imaging. Pediatr Anesth. 2010;20(4):330-337.
18. Cote CJ, Cohen IT, Suresh S, et al. A comparison of three doses of a commercially prepared oral midazolam syrup in children. Anesth Analg. 2002;94(1):37-43.
19. Silver T, Wilson C, et al. Evaluation of two dosages of oral midazolam as a conscious sedation for physically and neurologically compromised pediatric dental patients. Pediatr Dent. 1994;16(5):350-359.
20. Damle SG, Gandhi M, et al. Comparison of oral ketamine and oral midazolam as sedative agents in pediatric dentistry. J Indian Soc Pedod Prev Dent. 2008;26(3):97-101.
21. Sheta SA, Alsaheer MD. Oral Midazolam Premedication for Children Undergoing General Anaesthesia for Dental Care. Int J Pediatr. 2009;2009:1-7.
22. Shapiro J, Kupietzky A, et al. Comparison of oral midazolam with and without hydroxyzine in the sedation of pediatric dental patients. Pediatr Dent. 2004;26(6):492-496.
23. Masue T, Shimokura H, Fukao I, Kasuya S, Kasuya Y, Dohi S. Oral high-dose midazolam premedication for infants and children undergoing cardiovascular surgery. Paediatr Anaesth. 2003;13(8):662-667.
24. Ghai B, Grandhe RP, Kumar A, Chari P. Comparative evaluation of midazolam and ketamine with midazolam alone as oral premedication. Pediatr Anesth. 2005;15(7):554-559.
25. Guittet C, Manso M, Burton I, Granier L-A, Marcon F. A two-way randomized cross-over pharmacokinetic and pharmacodynamic study of an innovative oral solution of midazolam (ADV6209). Pharm Res. 2017;34(9):1840-1848.
26. Debnath S, Pande Y. A comparative study of oral premedication in children with ketamine and midazolam. Indian J Anaesth. 2003;47(1):45-47.
27. Alderson PJ, Lerman J. Oral premedication for paediatric ambulatory anaesthesia: a comparison of midazolam and ketamine. Can J Anaesth. 1994;41(3):221-226.
28. Darlong V, Shende D, Subramanyam MS, Sunder R, Naik A. Oral ketamine or midazolam or low dose combination for premedication in children. Anaesth Intensive Care. 2004;32(2):246-249.

29. Funk W, Jakob W, Riedl T, Taeger K. Oral preanaesthetic medication for children: double-blind randomized study of a combination of midazolam and ketamine vs midazolam or ketamine alone. Br J Anaesth. 2000;84(3):335-340.

30. Talon MD, Woodson LC, Sherwood ER, Aarsland A, McRae L, Benham T. Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery. J Burn Care Res. 2009;30(4):599-605.

31. Kogan A, Katz J, Efrat R, Eidelman LA. Premedication with midazolam in young children: a comparison of four routes of administration. Paediatr Anaesth. 2002;12(8):685-689.

32. Klein EJ, Brown JC, Kobayashi A, Osincup D, Seidel K. A randomized clinical trial comparing oral, aerosolized intranasal, and aerosolized buccal midazolam. Ann Emerg Med. 2011;58(4):323-329.

33. Darlong V, Shende D, Singh M, Garg R, Pandey R, Punj J. Low- versus high-dose combination of midazolam-ketamine for oral premedication in children for ophthalmologic surgeries. Singapore Med J. 2011;52(7):512-516.

34. Levine MF, Spahr-Schopfer IA, Hartley E, Lerman J, MacPherson B. Oral midazolam premedication in children: the minimum time interval for separation from parents. Can J Anaesth. 1993;40(8):726-729.

35. Levine MF, Hartley EJ, Macpherson BA, Burrows FA, Lerman J. Oral midazolam premedication for children with congenital cyanotic heart disease undergoing cardiac surgery: a comparative study. Can J Anaesth. 1993;40(10):934-938.

36. Wilson KE, Welbury RR, Girdler NM. A randomised, controlled, crossover trial of oral midazolam and nitrous oxide for paediatric dental sedation. Anaesthesia. 2002;57(9):860-867.

37. Wilson KE, Girdler NM, Welbury RR. A comparison of oral midazolam and nitrous oxide sedation for dental extractions in children. Anaesthesia. 2006;61(12):1138-1144.

How to cite this article: Manso MA, Guittet C, Vandenhende F, Granier L-A. Efficacy of oral midazolam for minimal and moderate sedation in pediatric patients: A systematic review. Pediatr Anesth. 2019;29:1094–1106. https://doi.org/10.1111/pan.13747